Based on its core modeling technology, Simphotek provides critical light treatment planning information to physicians using a combination of laser light and light drugs to produce a photo-chemical reaction that kills cancer cells. Light therapy, a.k.a. Photodynamic Therapy, or PDT, is significantly less toxic to the patient compared to conventional cancer therapies and can be repeated as many times as needed as adjunct or prime therapy. Simphotek team believes that personalized treatment of cancer with light, enabled with its accurate dosimetry, will make PDT a standard alternative cancer cure option offered by cancer facilities of any size and level. Simphotek Inc owns a patented simulation technology that enables accurate modeling of photonic interactions in photo-activated materials and devices. Researchers, engineers and product managers use our technology to analyze and understand complex interaction of light with photo-activated materials, and to design and optimize novel promising materials via computer simulation avoiding expensive and time-consuming fabrication and laboratory testing.